Venus Concept Reduces Debt with Equity Exchange

The latest update is out from Venus Concept ( (VERO) ).

On September 30, 2025, Venus Concept Inc. completed a debt-to-equity exchange agreement with Madryn Health Partners, converting $11.48 million of subordinated convertible notes into 545,335 shares of Series Y preferred stock. This transaction reduced Venus Concept’s total debt by 24%, enhancing its financial position and supporting its strategic initiatives for long-term growth and profitability. The exchange agreement also involved amendments to existing loan agreements, providing additional financial flexibility and extending loan maturity dates.

The most recent analyst rating on (VERO) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Venus Concept stock, see the VERO Stock Forecast page.

Spark’s Take on VERO Stock

According to Spark, TipRanks’ AI Analyst, VERO is a Neutral.

Venus Concept’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues, high operational costs, and substantial net losses. Technical analysis provides a neutral outlook, while valuation metrics highlight significant challenges due to negative profitability. Despite some strategic efforts to improve financial health, the company’s financial instability remains a major concern.

To see Spark’s full report on VERO stock, click here.

More about Venus Concept

Venus Concept is a global leader in medical aesthetic technology, offering a diverse range of minimally invasive and non-invasive aesthetic and hair restoration technologies. The company operates in over 60 countries and provides products such as Venus Versa, Venus Legacy, and the ARTAS iX Robotic Hair Restoration system.

Average Trading Volume: 48,290

Technical Sentiment Signal: Sell

Current Market Cap: $4.52M

Learn more about VERO stock on TipRanks’ Stock Analysis page.